Ratings MEDICLIN AG

Equities

MED

DE0006595101

Market Closed - Xetra Other stock markets 11:36:11 2024-04-26 am EDT			5-day change	1st Jan Change
2.82 ^EUR	0.00%		+4.44%	+2.92%

Mar. 27	MEDICLIN Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 22	Mediclin to Buy Rehabilitation Clinic in Germany	MT

Strengths

The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company does not generate enough profits, which is an alarming weak point.
The company is not the most generous with respect to shareholders' compensation.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MEDICLIN AG	+2.92%	143M	-	C
AIER EYE HOSPITAL GROUP CO., LTD.	-20.16%	15.76B		B+
BANGKOK DUSIT MEDICAL SERVICES	+4.50%	12.34B		B
IHH HEALTHCARE	+3.98%	11.52B		B+
APOLLO HOSPITALS ENTERPRISE LIMITED	+9.72%	11.02B		B+
ENCOMPASS HEALTH CORPORATION	+23.61%	8.28B		B
RAMSAY HEALTH CARE LIMITED	-2.19%	7.8B		A-
MOUWASAT MEDICAL SERVICES COMPANY	+20.75%	7.2B		D
THE ENSIGN GROUP, INC.	+4.49%	6.67B		B-
GLOBAL HEALTH LIMITED	+50.89%	4.64B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes